{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T15:08:41Z","timestamp":1784041721579,"version":"3.55.0"},"reference-count":87,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["34,099"],"award-info":[{"award-number":["34,099"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["31443"],"award-info":[{"award-number":["31443"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.ctrv.2026.103156","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T04:05:52Z","timestamp":1778817952000},"page":"103156","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Adjuvant chemotherapy in stage I triple-negative breast cancer: A systematic review and meta-analysis of survival outcomes"],"prefix":"10.1016","volume":"148","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9126-8325","authenticated-orcid":false,"given":"Flavia","family":"Jacobs","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"Polymeropoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo De","family":"Monte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Ligorio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Provenzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Armani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Fotia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Mazzoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Coppola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Bottelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthea","family":"Iacobucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Bianchessi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Abate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia V.","family":"Bianchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Capri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Ferraris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Martelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Secondo","family":"Folli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Vingiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giancarlo","family":"Pruneri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalba","family":"Miceli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Vernieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ctrv.2026.103156_b0005","first-page":"477","article-title":"Breast cancer statistics 2024","volume":"74","author":"Giaquinto","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ctrv.2026.103156_b0010","doi-asserted-by":"crossref","unstructured":"Foulkes WD, Smith IE, Reis-Filho JS. Triple-Negative Breast Cancer. N Engl J Med. 11 novembre 2010;363(20):1938\u201348. doi:10.1056\/NEJMra1001389.","DOI":"10.1056\/NEJMra1001389"},{"key":"10.1016\/j.ctrv.2026.103156_b0015","doi-asserted-by":"crossref","unstructured":"Lin NU, Vanderplas A, Hughes ME, Theriault RL, Edge SB, Wong YN, et al. Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network. Cancer. 15 novembre 2012;118(22):5463\u201372. doi:10.1002\/cncr.27581 PubMed PMID: 22544643; PubMed Central PMCID: PMC3611659.","DOI":"10.1002\/cncr.27581"},{"key":"10.1016\/j.ctrv.2026.103156_b0020","doi-asserted-by":"crossref","unstructured":"Bardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K, Oliveira M, et al. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. N Engl J Med. 22 aprile 2021;384(16):1529\u201341. doi:10.1056\/NEJMoa2028485 PubMed PMID: 33882206.","DOI":"10.1056\/NEJMoa2028485"},{"key":"10.1016\/j.ctrv.2026.103156_b0025","doi-asserted-by":"crossref","unstructured":"Bardia A, Rugo HS, Tolaney SM, Loirat D, Punie K, Oliveira M, et al. Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression. J Clin Oncol. 20 maggio 2024;42(15):1738\u201344. doi:10.1200\/JCO.23.01409.","DOI":"10.1200\/JCO.23.01409"},{"key":"10.1016\/j.ctrv.2026.103156_b0030","doi-asserted-by":"crossref","unstructured":"Cort\u00e9s J, Punie K, Barrios C, Hurvitz SA, Schneeweiss A, Sohn J, et al. Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer. N Engl J Med. 13 novembre 2025;393(19):1912\u201325. doi:10.1056\/NEJMoa2511734 PubMed PMID: 41124233.","DOI":"10.1056\/NEJMoa2511734"},{"issue":"35","key":"10.1016\/j.ctrv.2026.103156_b0035","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.2217\/fon-2023-0228","article-title":"TROPION-Breast02: Datopotamab deruxtecan for locally recurrent inoperable or metastatic triple-negative breast cancer","volume":"19","author":"Dent","year":"2023","journal-title":"Future Oncol Lond Engl novembre"},{"key":"10.1016\/j.ctrv.2026.103156_b0040","doi-asserted-by":"crossref","unstructured":"Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence. Clin Cancer Res. 1 agosto 2007;13(15):4429\u201334. doi:10.1158\/1078-0432.CCR-06-3045.","DOI":"10.1158\/1078-0432.CCR-06-3045"},{"key":"10.1016\/j.ctrv.2026.103156_b0045","doi-asserted-by":"crossref","unstructured":"Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet Lond Engl. 12 luglio 2014;384(9938):164\u201372. doi:10.1016\/S0140-6736(13)62422-8 PubMed PMID: 24529560.","DOI":"10.1016\/S0140-6736(13)62422-8"},{"key":"10.1016\/j.ctrv.2026.103156_b0050","doi-asserted-by":"crossref","unstructured":"Schmid P, Cortes J, Pusztai L, McArthur H, K\u00fcmmel S, Bergh J, et al. Pembrolizumab for Early Triple-Negative Breast Cancer. N Engl J Med. 27 febbraio 2020;382(9):810\u201321. doi:10.1056\/NEJMoa1910549 PubMed PMID: 32101663.","DOI":"10.1056\/NEJMoa1910549"},{"key":"10.1016\/j.ctrv.2026.103156_b0055","doi-asserted-by":"crossref","unstructured":"Schmid P, Cortes J, Dent R, Pusztai L, McArthur H, K\u00fcmmel S, et al. Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer. N Engl J Med. 10 febbraio 2022;386(6):556\u201367. doi:10.1056\/NEJMoa2112651 PubMed PMID: 35139274.","DOI":"10.1056\/NEJMoa2112651"},{"key":"10.1016\/j.ctrv.2026.103156_b0060","doi-asserted-by":"crossref","unstructured":"Schmid P, Cortes J, Dent R, McArthur H, Pusztai L, K\u00fcmmel S, et al. Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer. N Engl J Med. 28 novembre 2024;391(21):1981\u201391. doi:10.1056\/NEJMoa2409932 PubMed PMID: 39282906.","DOI":"10.1056\/NEJMoa2409932"},{"key":"10.1016\/j.ctrv.2026.103156_b0065","doi-asserted-by":"crossref","unstructured":"Loibl S, Andr\u00e9 F, Bachelot T, Barrios CH, Bergh J, Burstein HJ, et al. Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up\u2606. Ann Oncol. 1 febbraio 2024;35(2):159\u201382. doi:10.1016\/j.annonc.2023.11.016.","DOI":"10.1016\/j.annonc.2023.11.016"},{"key":"10.1016\/j.ctrv.2026.103156_b0070","unstructured":"Burstein HJ, Curigliano G, Th\u00fcrlimann B, Weber WP, Poortmans P, Regan MM, et al. Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. Ann Oncol Off J Eur Soc Med Oncol. ottobre 2021;32(10):1216\u201335. doi:10.1016\/j.annonc.2021.06.023 PubMed PMID: 34242744; PubMed Central PMCID: PMC9906308."},{"key":"10.1016\/j.ctrv.2026.103156_b0075","doi-asserted-by":"crossref","unstructured":"Cortina CS, Lloren JI, Rogers C, Johnson MK, Cobb AN, Huang CC, et al. Does Neoadjuvant Chemotherapy in Clinical T1\u2013T2 N0 Triple-Negative Breast Cancer Increase the Extent of Axillary Surgery? Ann Surg Oncol. 2024;31(5):3128\u201340. Located at: Embase. doi:10.1245\/s10434-024-14914-9.","DOI":"10.1245\/s10434-024-14914-9"},{"issue":"12","key":"10.1016\/j.ctrv.2026.103156_b0080","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/j.annonc.2025.09.007","article-title":"Tailoring treatment to cancer risk and patient preference: the 2025 St Gallen International Breast Cancer Consensus Statement on individualizing therapy for patients with early breast cancer","volume":"36","author":"Burstein","year":"2025","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103156_b0085","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyae346","article-title":"Benefit of adjuvant chemotherapy forT1cN0M0 and selectedT1bN0M0 triple-negative breast cancer: a nationwide cancer registry-based study","volume":"30","author":"Lo","year":"2025","journal-title":"Oncologist"},{"key":"10.1016\/j.ctrv.2026.103156_b0090","doi-asserted-by":"crossref","unstructured":"An X, Lei X, Huang R, Luo R, Li H, Xu F, et al. Adjuvant chemotherapy for small, lymph node-negative, triple-negative breast cancer: A single-center study and a meta-analysis of the published literature. Cancer. 15 agosto 2020;126 Suppl 16:3837\u201346. doi:10.1002\/cncr.32878 PubMed PMID: 32710666.","DOI":"10.1002\/cncr.32878"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103156_b0095","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1093\/oncolo\/oyab003","article-title":"Early-stage triple-negative breast cancer: Time to optimize personalized strategies","volume":"27","author":"Abuhadra","year":"2022","journal-title":"The Oncologist 3 febbraio"},{"key":"10.1016\/j.ctrv.2026.103156_b0100","doi-asserted-by":"crossref","unstructured":"Fu WF, Chen QX, Wang XX, Zhang J, Song CG. The Survival Outcomes of T1aN0M0 Triple-Negative Breast Cancer With Adjuvant Chemotherapy. Front Oncol. 30 settembre 2020;10:1753. doi:10.3389\/fonc.2020.01753.","DOI":"10.3389\/fonc.2020.01753"},{"key":"10.1016\/j.ctrv.2026.103156_b0105","doi-asserted-by":"crossref","unstructured":"Vaz-Luis I, Ottesen RA, Hughes ME, Mamet R, Burstein HJ, Edge SB, et al. Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study. J Clin Oncol Off J Am Soc Clin Oncol. 10 luglio 2014;32(20):2142\u201350. doi:10.1200\/JCO.2013.53.1608 PubMed PMID: 24888816; PubMed Central PMCID: PMC4076026.","DOI":"10.1200\/JCO.2013.53.1608"},{"key":"10.1016\/j.ctrv.2026.103156_b0110","doi-asserted-by":"crossref","unstructured":"Oladeru OT, Singh AK, Ma SJ. Association of Adjuvant Chemotherapy With Overall Survival Among Women With Small, Node-Negative, Triple-Negative Breast Cancer. JAMA Netw Open. 14 settembre 2020;3(9):e2016247. doi:10.1001\/jamanetworkopen.2020.16247.","DOI":"10.1001\/jamanetworkopen.2020.16247"},{"key":"10.1016\/j.ctrv.2026.103156_b0115","doi-asserted-by":"crossref","unstructured":"Tarantino P, Leone J, Vallejo CT, Freedman RA, Waks AG, Mart\u00ednez-S\u00e1ez O, et al. Prognosis and treatment outcomes for patients with stage IA triple-negative breast cancer. Npj Breast Cancer. 4 aprile 2024;10(1):26. doi:10.1038\/s41523-024-00634-6.","DOI":"10.1038\/s41523-024-00634-6"},{"key":"10.1016\/j.ctrv.2026.103156_b0120","doi-asserted-by":"crossref","unstructured":"Allison KH, Hammond MEH, Dowsett M, McKernin SE, Carey LA, Fitzgibbons PL, et al. Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO\/CAP Guideline Update. J Clin Oncol Off J Am Soc Clin Oncol. 20 aprile 2020;38(12):1346\u201366. doi:10.1200\/JCO.19.02309 PubMed PMID: 31928404.","DOI":"10.1200\/JCO.19.02309"},{"issue":"22","key":"10.1016\/j.ctrv.2026.103156_b0125","doi-asserted-by":"crossref","first-page":"3867","DOI":"10.1200\/JCO.22.02864","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: ASCO\u2013college of American pathologists guideline update","volume":"41","author":"Wolff","year":"2023","journal-title":"J Clin Oncol agosto"},{"key":"10.1016\/j.ctrv.2026.103156_b0130","doi-asserted-by":"crossref","unstructured":"Hayden JA, van der Windt DA, Cartwright JL, C\u00f4t\u00e9 P, Bombardier C. Assessing bias in studies of prognostic factors. Ann Intern Med. 19 febbraio 2013;158(4):280\u20136. doi:10.7326\/0003-4819-158-4-201302190-00009 PubMed PMID: 23420236.","DOI":"10.7326\/0003-4819-158-4-201302190-00009"},{"key":"10.1016\/j.ctrv.2026.103156_b0135","doi-asserted-by":"crossref","unstructured":"Lee CH, Cook S, Lee JS, Han B. Comparison of Two Meta-Analysis Methods: Inverse-Variance-Weighted Average and Weighted Sum of Z-Scores. Genomics Inform. 30 dicembre 2016;14(4):173\u201380. doi:10.5808\/GI.2016.14.4.173.","DOI":"10.5808\/GI.2016.14.4.173"},{"key":"10.1016\/j.ctrv.2026.103156_b0140","doi-asserted-by":"crossref","unstructured":"COCHRAN WG. THE COMPARISON OF PERCENTAGES IN MATCHED SAMPLES. Biometrika. 1 dicembre 1950;37(3\u20134):256\u201366. doi:10.1093\/biomet\/37.3-4.256.","DOI":"10.1093\/biomet\/37.3-4.256"},{"issue":"11","key":"10.1016\/j.ctrv.2026.103156_b0145","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"key":"10.1016\/j.ctrv.2026.103156_b0150","doi-asserted-by":"crossref","unstructured":"Raggi D, Miceli R, Sonpavde G, Giannatempo P, Mariani L, Galsky MD, et al. Second-line single-agent versus doublet chemotherapy as salvage therapy for metastatic urothelial cancer: a systematic review and meta-analysis. Ann Oncol. 1 gennaio 2016;27(1):49\u201361. doi:10.1093\/annonc\/mdv509.","DOI":"10.1093\/annonc\/mdv509"},{"key":"10.1016\/j.ctrv.2026.103156_b0155","doi-asserted-by":"crossref","unstructured":"Shi L, Lin L. The trim-and-fill method for publication bias: practical guidelines and recommendations based on a large database of meta-analyses. Medicine (Baltimore). 7 giugno 2019;98(23):e15987. doi:10.1097\/MD.0000000000015987 PubMed PMID: 31169736; PubMed Central PMCID: PMC6571372.","DOI":"10.1097\/MD.0000000000015987"},{"key":"10.1016\/j.ctrv.2026.103156_b0160","doi-asserted-by":"crossref","unstructured":"Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 13 settembre 1997;315(7109):629\u201334. doi:10.1136\/bmj.315.7109.629 PubMed PMID: 9310563.","DOI":"10.1136\/bmj.315.7109.629"},{"issue":"7","key":"10.1016\/j.ctrv.2026.103156_b0165","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.clbc.2023.08.002","article-title":"Assessment of use and impact of chemotherapy in lymph node-negative, T1a triple-negative breast cancer","volume":"23","author":"Bravo-Solarte","year":"2023","journal-title":"Clin Breast Cancer ottobre"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103156_b0170","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s10549-023-07132-6","article-title":"Benefit of adjuvant chemotherapy in lymph node-negative, T1b and T1c triple-negative breast cancer","volume":"203","author":"Carbajal-Ochoa","year":"2024","journal-title":"Breast Cancer Res Treat gennaio"},{"key":"10.1016\/j.ctrv.2026.103156_b0175","doi-asserted-by":"crossref","unstructured":"Cheng SHC, Yu BL, Horng CF, Tsai SY, Chen CM, Chu NM, et al. Long-term survival and stage I breast cancer subtypes. J Cancer Res Pract. 1 marzo 2016;3(1):1\u20138. doi:10.1016\/j.jcrpr.2015.10.005.","DOI":"10.1016\/j.jcrpr.2015.10.005"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103156_b0180","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.clbc.2015.10.001","article-title":"Analysis of risk of recurrence by subtype in\u2264 1-cm Breast Tumors","volume":"16","author":"Colonna","year":"2016","journal-title":"Clin Breast Cancer giugno"},{"key":"10.1016\/j.ctrv.2026.103156_b0185","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ejca.2017.06.043","article-title":"Adjuvant chemotherapy in pT1ab node-negative triple-negative breast carcinomas: Results of a nationalmulti-institutional retrospective study","volume":"84","author":"de Nonneville","year":"1990","journal-title":"Eur J Cancer Oxf Engl"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103156_b0190","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s10549-020-05776-2","article-title":"Evaluation of a beneficial effect of adjuvant chemotherapy in patients with stage I triple-negative breast cancer: a population-based study using the SEER 18 database","volume":"183","author":"Du","year":"2020","journal-title":"Breast Cancer Res Treat settembre"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103156_b0195","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s10549-021-06481-4","article-title":"Benefit of adjuvant chemotherapy in node-negative T1a versus T1b and T1c triple-negative breast cancer","volume":"192","author":"Fasano","year":"2022","journal-title":"Breast Cancer Res Treat febbraio"},{"key":"10.1016\/j.ctrv.2026.103156_b0200","doi-asserted-by":"crossref","unstructured":"Ho AY, Gupta G, King TA, Perez CA, Patil SM, Rogers KH, et al. Favorable prognosis in patients with T1a\/T1bN0 triple-negative breast cancers treated with multimodality therapy. Cancer. 15 ottobre 2012;118(20):4944\u201352. doi:10.1002\/cncr.27480 PubMed PMID: 22392492.","DOI":"10.1002\/cncr.27480"},{"issue":"5","key":"10.1016\/j.ctrv.2026.103156_b0205","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/j.1524-4741.2009.00789.x","article-title":"T1N0 triple negative breast cancer: risk of recurrence and adjuvant chemotherapy","volume":"15","author":"Kaplan","year":"2009","journal-title":"Breast J ottobre"},{"key":"10.1016\/j.ctrv.2026.103156_b0210","doi-asserted-by":"crossref","unstructured":"Lan T, Lu Y, Luo H, Yang O, He J, Xu H, et al. The role of chemotherapy in patients with T1bN0M0 triple-negative breast cancer: a real-world competing risk analysis. J Cancer. 1 gennaio 2021;12(1):10\u20137. doi:10.7150\/jca.52540 PubMed PMID: 33391398; PubMed Central PMCID: PMC7738821.","DOI":"10.7150\/jca.52540"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103156_b0215","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s10549-017-4499-7","article-title":"Impact of histopathology, tumor-infiltrating lymphocytes, and adjuvant chemotherapy on prognosis of triple-negative breast cancer","volume":"167","author":"Leon-Ferre","year":"2018","journal-title":"Breast Cancer Res Treat gennaio"},{"key":"10.1016\/j.ctrv.2026.103156_b0220","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.breast.2021.06.009","article-title":"Triple-negative breast cancer outcomes: Does AJCC 8th staging improve chemotherapy decision-making","volume":"59","author":"Lian","year":"2021","journal-title":"Breast Edinb Scotl ottobre"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103156_b0225","article-title":"Triple negative breast cancer-Adjuvant chemotherapy use and survival outcomes in Stage IA disease","volume":"77","author":"Patel","year":"2017","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2026.103156_b0230","doi-asserted-by":"crossref","unstructured":"Pfob A, Surovtsova I, Kokh DB, Heil J, Banys-Paluchowski M, Morakis P. Use of chemotherapy and loco-regional therapy in stage IA triple-negative breast cancer and their association with oncologic outcomes: A cancer registry study. Int J Cancer. 1 febbraio 2025;156(3):587\u201397. doi:10.1002\/ijc.35189 PubMed PMID: 39291633.","DOI":"10.1002\/ijc.35189"},{"key":"10.1016\/j.ctrv.2026.103156_b0235","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.breast.2018.11.011","article-title":"Effects of adjuvant chemotherapy in T1N0M0 triple-negative breast cancer","volume":"43","author":"Ren","year":"2019","journal-title":"Breast Edinb Scotl febbraio"},{"key":"10.1016\/j.ctrv.2026.103156_b0240","doi-asserted-by":"crossref","unstructured":"Shum K, Hussein A, Hamm C. Are we overtreating stage I triple-negative breast cancer in Ontario? A population-based retrospective epidemiological analysis using the ICES database. Med Oncol Northwood Lond Engl. 29 settembre 2022;39(12):228. doi:10.1007\/s12032-022-01829-2 PubMed PMID: 36175693.","DOI":"10.1007\/s12032-022-01829-2"},{"key":"10.1016\/j.ctrv.2026.103156_b0245","doi-asserted-by":"crossref","unstructured":"Steenbruggen TG, van Werkhoven E, van Ramshorst MS, Dezentj\u00e9 VO, Kok M, Linn SC, et al. Adjuvant chemotherapy in small node-negative triple-negative breast cancer. Eur J Cancer Oxf Engl 1990. agosto 2020;135:66\u201374. doi:10.1016\/j.ejca.2020.04.033 PubMed PMID: 32554215.","DOI":"10.1016\/j.ejca.2020.04.033"},{"issue":"5","key":"10.1016\/j.ctrv.2026.103156_b0250","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0197523","article-title":"The effect of adjuvant chemotherapy on survival in Korean patients with node negative T1c, triple negative breast cancer","volume":"13","author":"Lim","year":"2018","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.ctrv.2026.103156_b0255","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.21037\/gs-22-409","article-title":"Exploration of prognostic factors and the value of adjuvant chemotherapy in T1a,bN0M0 triple-negative breast cancer: a prospective cohort study based on the SEER database","volume":"11","author":"Wu","year":"2022","journal-title":"Gland Surg agosto"},{"key":"10.1016\/j.ctrv.2026.103156_b0260","doi-asserted-by":"crossref","unstructured":"Wu C, Huang O, Wu J, Shen K, Chen X, Zhu S. Tumor size is associated with adjuvant chemotherapy benefit in T1N0M0 triple-negative breast cancer: a multicenter and propensity score matched analysis. Gland Surg. 30 ottobre 2023;12(10):1375\u201386. doi:10.21037\/gs-23-189 PubMed PMID: 38021197; PubMed Central PMCID: PMC10660177.","DOI":"10.21037\/gs-23-189"},{"key":"10.1016\/j.ctrv.2026.103156_b0265","doi-asserted-by":"crossref","unstructured":"Zhai Z, Zheng Y, Yao J, Liu Y, Ruan J, Deng Y, et al. Evaluation of Adjuvant Treatments for T1 N0 M0 Triple-Negative Breast Cancer. JAMA Netw Open. 2 novembre 2020;3(11):e2021881. doi:10.1001\/jamanetworkopen.2020.21881 PubMed PMID: 33211105; PubMed Central PMCID: PMC7677762.","DOI":"10.1001\/jamanetworkopen.2020.21881"},{"key":"10.1016\/j.ctrv.2026.103156_b0270","doi-asserted-by":"crossref","unstructured":"Zhang J, Wang W, Wang J, Luo Y, Chen S, Ma F, et al. Survival Outcome and Impact of Chemotherapy in T1 Node-Negative Triple-Negative Breast Cancer: A SEER Database Analysis. J Oncol. 2020;2020((Zhang J., zhangjingyiyi13@163.com; Wang W., wangwennazi@126.com; Wang J., wangjiayu8778@sina.com; Luo Y., dryangluo@163.com; Chen S., css95669@hotmail.com; Ma F., drmafei@126.com; Xu B., xubinghe@medmail.com.cn; Fan Y., fanyingfy@medmail.com.cn) Department of Medical Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China). Located at: Embase. doi:10.1155\/2020\/8880727.","DOI":"10.1155\/2020\/8880727"},{"key":"10.1016\/j.ctrv.2026.103156_b0275","doi-asserted-by":"crossref","unstructured":"Zhang Y, Liu X, Ma M, Chen C, Wang X. Survival benefit of adjuvant chemotherapy in elderly patients with stage I triple-negative breast cancer: a cohort study based on the SEER database. Transl Cancer Res. 31 luglio 2023;12(7):1741\u201352. doi:10.21037\/tcr-23-123 PubMed PMID: 37588733; PubMed Central PMCID: PMC10425647.","DOI":"10.21037\/tcr-23-123"},{"issue":"6","key":"10.1016\/j.ctrv.2026.103156_b0280","doi-asserted-by":"crossref","first-page":"691","DOI":"10.6004\/jnccn.2022.0030","article-title":"Breast cancer, version 3.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"Gradishar","year":"2022","journal-title":"J Natl Compr Cancer Netw JNCCN giugno"},{"key":"10.1016\/j.ctrv.2026.103156_b0285","doi-asserted-by":"crossref","unstructured":"Li J, Hao C, Wang K, Zhang J, Chen J, Liu Y, et al. Chinese Society of Clinical Oncology (CSCO) Breast Cancer guidelines 2024. Transl Breast Cancer Res. 30 luglio 2024;5(0). doi:10.21037\/tbcr-24-31.","DOI":"10.21037\/tbcr-24-31"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103156_b0290","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s10549-017-4159-y","article-title":"Risk factors associated with the triple-negative breast cancer subtype within four race\/ethnicities","volume":"163","author":"Parise","year":"2017","journal-title":"Breast Cancer Res Treat maggio"},{"key":"10.1016\/j.ctrv.2026.103156_b0295","doi-asserted-by":"crossref","unstructured":"Gulbahce HE, Bernard PS, Weltzien EK, Factor RE, Kushi LH, Caan BJ, et al. Differences in molecular features of triple-negative breast cancers based on the age at diagnosis. Cancer. 15 dicembre 2018;124(24):4676\u201384. doi:10.1002\/cncr.31776 PubMed PMID: 30311638; PubMed Central PMCID: PMC6294689.","DOI":"10.1002\/cncr.31776"},{"key":"10.1016\/j.ctrv.2026.103156_b0300","article-title":"Effects of adjuvant chemotherapy on recurrence rate in T1abN0M0 triple-negative breast cancer: A meta-analysis","volume":"25","author":"Yang","year":"2020","journal-title":"Cancer Treat Res Commun"},{"key":"10.1016\/j.ctrv.2026.103156_b0305","doi-asserted-by":"crossref","unstructured":"Gouveia MC, Scaranti M, Migliavacca Zucchetti B, Bonadio RC, Barroso-Sousa R, Leone JP. Unveiling the paradigm shift: systemic treatment strategies in small, node-negative breast cancer. NPJ Breast Cancer. 16 maggio 2025;11:44. doi:10.1038\/s41523-025-00761-8 PubMed PMID: 40379683; PubMed Central PMCID: PMC12084305.","DOI":"10.1038\/s41523-025-00761-8"},{"issue":"8","key":"10.1016\/j.ctrv.2026.103156_b0310","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1093\/annonc\/mdv239","article-title":"Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials","volume":"26","author":"Dieci","year":"2015","journal-title":"Ann Oncol agosto"},{"key":"10.1016\/j.ctrv.2026.103156_b0315","doi-asserted-by":"crossref","unstructured":"de Jong VMT, Wang Y, Ter Hoeve ND, Opdam M, Stathonikos N, J\u00f3\u017awiak K, et al. Prognostic Value of Stromal Tumor-Infiltrating Lymphocytes in Young, Node-Negative, Triple-Negative Breast Cancer Patients Who Did Not Receive (neo)Adjuvant Systemic Therapy. J Clin Oncol Off J Am Soc Clin Oncol. 20 luglio 2022;40(21):2361\u201374. doi:10.1200\/JCO.21.01536 PubMed PMID: 35353548; PubMed Central PMCID: PMC9287283.","DOI":"10.1200\/JCO.21.01536"},{"issue":"12","key":"10.1016\/j.ctrv.2026.103156_b0320","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1093\/annonc\/mdz395","article-title":"Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy","volume":"30","author":"Park","year":"2019","journal-title":"Ann Oncol dicembre"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103156_b0325","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s10549-014-3185-2","article-title":"The prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancer: a meta-analysis","volume":"148","author":"Ibrahim","year":"2014","journal-title":"Breast Cancer Res Treat dicembre"},{"key":"10.1016\/j.ctrv.2026.103156_b0330","doi-asserted-by":"crossref","unstructured":"Gao G, Wang Z, Qu X, Zhang Z. Prognostic value of tumor-infiltrating lymphocytes in patients with triple-negative breast cancer: a systematic review and meta-analysis. BMC Cancer. 4 marzo 2020;20(1):179. doi:10.1186\/s12885-020-6668-z.","DOI":"10.1186\/s12885-020-6668-z"},{"key":"10.1016\/j.ctrv.2026.103156_b0335","doi-asserted-by":"crossref","unstructured":"Adams S, Gray RJ, Demaria S, Goldstein L, Perez EA, Shulman LN, et al. Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199. J Clin Oncol. 20 settembre 2014. Located at: world. doi:10.1200\/JCO.2013.55.0491.","DOI":"10.1200\/JCO.2013.55.0491"},{"key":"10.1016\/j.ctrv.2026.103156_b0340","unstructured":"Leon-Ferre RA, Jonas SF, Salgado R, Loi S, de Jong V, Carter JM, et al. Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer. JAMA. 2 aprile 2024;331(13):1135\u201344. doi:10.1001\/jama.2024.3056 PubMed PMID: 38563834; PubMed Central PMCID: PMC10988354."},{"key":"10.1016\/j.ctrv.2026.103156_b0345","doi-asserted-by":"crossref","unstructured":"Geurts VCM, Balduzzi S, Steenbruggen TG, Linn SC, Siesling S, Badve SS, et al. Tumor-Infiltrating Lymphocytes in Patients With Stage I Triple-Negative Breast Cancer Untreated With Chemotherapy. JAMA Oncol. 1 agosto 2024;10(8):1077\u201386. doi:10.1001\/jamaoncol.2024.1917 PubMed PMID: 38935352; PubMed Central PMCID: PMC11211993.","DOI":"10.1001\/jamaoncol.2024.1917"},{"key":"10.1016\/j.ctrv.2026.103156_b0350","unstructured":"The Netherlands Cancer Institute. OPTImaL:Optimisation of Treatment for Patients With Low Stage Triple-negative Breast Cancer With High Stromal Tumor-infiltrating Lymphocytes [Clinical trial registration] [Internet]. clinicaltrials.gov; aprile 2025 [citato 1 dicembre 2025]. Clinical trial registration no.: NCT06476119. Disponibile su: https:\/\/clinicaltrials.gov\/study\/NCT06476119."},{"key":"10.1016\/j.ctrv.2026.103156_b0355","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.breast.2020.07.003","article-title":"Prognosis of selected triple negative apocrine breast cancer patients who did not receive adjuvant chemotherapy","volume":"53","author":"Montagna","year":"2020","journal-title":"Breast Edinb Scotl ottobre"},{"issue":"18","key":"10.1016\/j.ctrv.2026.103156_b0360","doi-asserted-by":"crossref","first-page":"7523","DOI":"10.1002\/cam4.2634","article-title":"Prognosis in triple-negative apocrine carcinomas of the breast: A population-based study","volume":"8","author":"Wu","year":"2019","journal-title":"Cancer Med"},{"key":"10.1016\/j.ctrv.2026.103156_b0365","doi-asserted-by":"crossref","unstructured":"Vranic S, Gatalica Z. An Update on the Molecular and Clinical Characteristics of Apocrine Carcinoma of the Breast. Clin Breast Cancer. 1 giugno 2022;22(4):e576\u201385. doi:10.1016\/j.clbc.2021.12.009.","DOI":"10.1016\/j.clbc.2021.12.009"},{"issue":"11","key":"10.1016\/j.ctrv.2026.103156_b0370","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0140208","article-title":"Prognostic Role of Adjuvant Chemotherapy in Node-negative (N0), Triple-negative (TN), Medullary Breast Cancer (MBC) in the Korean Population","volume":"10","author":"Lim","year":"2015","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.ctrv.2026.103156_b0375","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1093\/annonc\/mds105","article-title":"Prognosis of medullary breast cancer: analysis of 13 International Breast Cancer Study Group (IBCSG) trials","volume":"23","author":"Huober","year":"2012","journal-title":"Ann Oncol novembre"},{"key":"10.1016\/j.ctrv.2026.103156_b0380","doi-asserted-by":"crossref","unstructured":"Chen H, Pu S, Wang L, Zhang H, Yan Y, He J, et al. A risk stratification model to predict chemotherapy benefit in medullary carcinoma of the breast: a population-based SEER database. Sci Rep. 3 luglio 2023;13(1):10704. doi:10.1038\/s41598-023-37915-2.","DOI":"10.1038\/s41598-023-37915-2"},{"key":"10.1016\/j.ctrv.2026.103156_b0385","doi-asserted-by":"crossref","unstructured":"Rypel J, Kubacka P, Myka\u0142a-Cie\u015bla J, Paj\u0105k J, Bulska-B\u0119dkowska W, Chudek J. Locally Advanced Adenoid Cystic Carcinoma of the Breast\u2014A Case Report with a Review of the Literature. Medicina (Mex). novembre 2023;59(11):2005. doi:10.3390\/medicina59112005.","DOI":"10.3390\/medicina59112005"},{"key":"10.1016\/j.ctrv.2026.103156_b0390","doi-asserted-by":"crossref","unstructured":"Chen QX, Li JJ, Wang XX, Lin PY, Zhang J, Song CG, et al. Similar outcomes between adenoid cystic carcinoma of the breast and invasive ductal carcinoma: a population-based study from the SEER 18 database. Oncotarget. 20 dicembre 2016;8(4):6206\u201315. doi:10.18632\/oncotarget.14052.","DOI":"10.18632\/oncotarget.14052"},{"key":"10.1016\/j.ctrv.2026.103156_b0395","doi-asserted-by":"crossref","unstructured":"Kim S, Sheth K, Yu X, Porterfield L, Vaughan EM. Clinical course and treatment outcomes in solid-basaloid adenoid cystic carcinoma of the breast: A systematic review and case report. Cancer Treat Rev. 1 dicembre 2025;141:103028. doi:10.1016\/j.ctrv.2025.103028.","DOI":"10.1016\/j.ctrv.2025.103028"},{"issue":"5","key":"10.1016\/j.ctrv.2026.103156_b0400","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.3390\/cancers15051556","article-title":"Clinical characteristics and prognosis of metaplastic breast cancer compared with invasive ductal carcinoma: A propensity-matched analysis","volume":"15","author":"Lee","year":"2023","journal-title":"Cancers gennaio"},{"key":"10.1016\/j.ctrv.2026.103156_b0405","doi-asserted-by":"crossref","unstructured":"Lan T, Lu Y, Zheng R, Shao X, Luo H, He J, et al. The Role of Adjuvant Chemotherapy in Metaplastic Breast Carcinoma: A Competing Risk Analysis of the SEER Database. Front Oncol. 26 aprile 2021;11. doi:10.3389\/fonc.2021.572230.","DOI":"10.3389\/fonc.2021.572230"},{"key":"10.1016\/j.ctrv.2026.103156_b0410","doi-asserted-by":"crossref","unstructured":"Zhang M, Yuan J, Wang M, Zhang M, Chen H. Chemotherapy is of prognostic significance to metaplastic breast cancer. Sci Rep. 12 gennaio 2024;14(1):1210. doi:10.1038\/s41598-024-51627-1.","DOI":"10.1038\/s41598-024-51627-1"},{"issue":"8","key":"10.1016\/j.ctrv.2026.103156_b0415","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1111\/cas.16208","article-title":"A comprehensive overview of metaplastic breast cancer: Features and treatments","volume":"115","author":"Yan","year":"2024","journal-title":"Cancer Sci"},{"key":"10.1016\/j.ctrv.2026.103156_b0420","doi-asserted-by":"crossref","unstructured":"Harper NW, Hodges KB, Stewart RL, Wu J, Huang B, O\u2019Connor KL, et al. Adjuvant Treatment of Triple-Negative Metaplastic Breast Cancer With Weekly Paclitaxel and Platinum Chemotherapy: Retrospective Case Review From a Single Institution. Clin Breast Cancer. 1 agosto 2019;19(4):e495\u2013500. doi:10.1016\/j.clbc.2019.05.009 PubMed PMID: 31208874.","DOI":"10.1016\/j.clbc.2019.05.009"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103156_b0425","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.annonc.2024.10.012","article-title":"TNBC-DX genomic test in early-stage triple-negative breast cancer treated with neoadjuvant taxane-based therapy","volume":"36","author":"Mart\u00edn","year":"2025","journal-title":"Ann Oncol Off J Eur Soc Med Oncol febbraio"},{"key":"10.1016\/j.ctrv.2026.103156_b0430","doi-asserted-by":"crossref","unstructured":"Mohanad M, Hamza HM, Bahnassy AA, Shaarawy S, Ahmed O, EL-Mezayen HA, et al. Molecular profiling of breast cancer methylation pattern in triple negative versus non- triple negative breast cancer. Sci Rep. 26 febbraio 2025;15(1):6894. doi:10.1038\/s41598-025-90150-9.","DOI":"10.1038\/s41598-025-90150-9"},{"key":"10.1016\/j.ctrv.2026.103156_b0435","doi-asserted-by":"crossref","unstructured":"Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, et al. Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. N Engl J Med. 12 luglio 2018;379(2):111\u201321. doi:10.1056\/NEJMoa1804710 PubMed PMID: 29860917; PubMed Central PMCID: PMC6172658.","DOI":"10.1056\/NEJMoa1804710"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737226000708?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737226000708?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T14:46:11Z","timestamp":1784040371000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737226000708"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":87,"alternative-id":["S0305737226000708"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2026.103156","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adjuvant chemotherapy in stage I triple-negative breast cancer: A systematic review and meta-analysis of survival outcomes","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2026.103156","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103156"}}